Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned an average recommendation of “Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $62.50.

JSPR has been the topic of several analyst reports. UBS Group initiated coverage on Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Royal Bank of Canada cut their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock.

Institutional Trading of Jasper Therapeutics

Several large investors have recently bought and sold shares of JSPR. Braidwell LP bought a new stake in Jasper Therapeutics during the 3rd quarter valued at approximately $9,091,000. Boxer Capital Management LLC bought a new stake in Jasper Therapeutics during the 4th quarter valued at approximately $7,483,000. Integral Health Asset Management LLC boosted its position in Jasper Therapeutics by 85.7% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock valued at $13,897,000 after acquiring an additional 300,000 shares in the last quarter. Ally Bridge Group NY LLC boosted its position in shares of Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares in the last quarter. Finally, Soleus Capital Management L.P. boosted its position in shares of Jasper Therapeutics by 11.2% in the 4th quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock worth $31,951,000 after purchasing an additional 150,755 shares in the last quarter. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Trading Up 2.0 %

JSPR opened at $5.49 on Monday. The company has a market cap of $82.47 million, a P/E ratio of -1.16 and a beta of 2.23. The business’s 50-day moving average price is $6.45 and its 200-day moving average price is $15.78. Jasper Therapeutics has a 12 month low of $4.55 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Equities research analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.